Drug Guide

Generic Name

Technetium Tc-99m Medronate

Brand Names Osteolite, Cis-mdp, Technetium Tc 99m Mpi Mdp, Amerscan Mdp Kit

Classification

Therapeutic: Diagnostic imaging agent

Pharmacological: Radioisotope

FDA Approved Indications

  • Bone scintigraphy for detection of metastatic bone disease, fractures, infections, and other bone abnormalities.

Mechanism of Action

Technetium Tc-99m Medronate is a radiopharmaceutical agent that localizes in bone tissue by chemisorption onto hydroxyapatite crystals, allowing for imaging of bones via gamma camera.

Dosage and Administration

Adult: Administer typically 20-30 mCi intravenously, with imaging performed 2-4 hours post-injection.

Pediatric: Dosage adjusted based on body weight and clinical judgment.

Geriatric: Adjust dose if renal function is compromised; no specific dose alterations mandated.

Renal Impairment: Use with caution; renal impairment may alter distribution and clearance.

Hepatic Impairment: No specific adjustments necessary.

Pharmacokinetics

Absorption: Administered intravenously; absorption is not applicable.

Distribution: Rapid distribution to bones and soft tissues.

Metabolism: Not metabolized; excreted unchanged.

Excretion: Primarily excreted via the kidneys in urine.

Half Life: Approximately 6 hours for Tc-99m; physical half-life of Tc-99m is about 6 hours.

Contraindications

  • Known hypersensitivity to Technetium Tc-99m Medronate or its components.

Precautions

  • Use caution in pregnant or breastfeeding women; exposure to radiation should be minimized.
  • Adjustments may be necessary in patients with compromised renal function.

Adverse Reactions - Common

  • Mild injection site pain, redness. (Uncommon)
  • Nausea or transient discomfort. (Uncommon)

Adverse Reactions - Serious

  • Allergic reactions including rash, itching, respiratory distress. (Rare)
  • Radiation-induced tissue injury, especially with extravasation. (Very rare)

Drug-Drug Interactions

  • None specifically known, but concurrent use of other radiopharmaceuticals should be managed carefully.

Drug-Food Interactions

  • None significant.

Drug-Herb Interactions

  • None identified.

Nursing Implications

Assessment: Monitor for allergic reactions, verify renal function, and ensure proper patient hydration.

Diagnoses:

  • Potential for allergic reaction, risk of radiation exposure.

Implementation: Ensure proper dosing, safe handling, and patient preparation/education.

Evaluation: Assess for side effects, verify proper imaging quality, and monitor renal function if indicated.

Patient/Family Teaching

  • Explain the purpose of the test and the importance of remaining still during imaging.
  • Advise hydration post-test to facilitate excretion.
  • Inform about minimal radiation exposure and precautions.

Special Considerations

Black Box Warnings:

  • Radiation exposure risk; use only when necessary.

Genetic Factors: Not specifically known to be affected by genetic factors.

Lab Test Interference: Minimal; no significant interference expected.

Overdose Management

Signs/Symptoms: No specific antidote; symptoms may include radiation exposure effects such as nausea or tissue damage if extravasation occurs.

Treatment: Supportive care, symptom management, and observation.

Storage and Handling

Storage: Store unopened kits at 2-8°C; protect from light.

Stability: Stable until expiration date provided by manufacturer.

This guide is for educational purposes only and is not intended for clinical use.